Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause Skin hyperpigmentation? 39 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Skin hyperpigmentation have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.1% of all adverse event reports for RUXOLITINIB.

39
Reports of Skin hyperpigmentation with RUXOLITINIB
0.1%
of all RUXOLITINIB reports
2
Deaths
8
Hospitalizations

How Dangerous Is Skin hyperpigmentation From RUXOLITINIB?

Of the 39 reports, 2 (5.1%) resulted in death, 8 (20.5%) required hospitalization, and 1 (2.6%) were considered life-threatening.

Is Skin hyperpigmentation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause Skin hyperpigmentation?

ADAPALENE (2,811) AVOBENZONE\OCTISALATE\OCTOCRYLENE (2,277) BIMATOPROST (189) AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE (182) DUPILUMAB (177) MINOCYCLINE (144) LENALIDOMIDE (142) METHOTREXATE (142) CAPECITABINE (136) COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES (120)

Which RUXOLITINIB Alternatives Have Lower Skin hyperpigmentation Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All Skin hyperpigmentation Reports All Drugs Causing Skin hyperpigmentation RUXOLITINIB Demographics